News and Events
-
ISTH 2025 Was Hot—in More Ways Than One!
Posted: July 23, 2025
ISTH 2025 brought the heat this year—both in scientific content and in temperature! While Washington, D.C. was under a heat advisory during the 33rd Congress of the International Society on Thrombosis and Haemostasis, that didn’t stop thousands of dedicated clinicians, researchers, and industry professionals, including a large team from DiaPharma, from coming together for an…
-
DiaPharma at ISTH 2025
Posted: June 27, 2025
See what we unveiled at ISTH 2025! VIEW VIDEO We are grateful for the opportunity to connect and discuss the latest advancements for the hemostasis laboratory at ISTH 2025. The science and collaboration were outstanding. Many thanks to all who worked so hard to make it a success! DiaPharma was proud to highlight: CLINICAL &…
-
Alcohol-related Clinical Trials & Early Liver Injury Biomarkers
Posted: June 23, 2025
Contributed by Abigail Kasberg, PhD Alcohol-related clinical trials play a fundamental role in advancing our understanding of the complex impact of alcohol consumption on human health. The prevalence of alcohol use is widespread, causing a systemic impact on the individual and affecting whole communities. Clinical trials are a means to investigate the mechanisms of alcohol-related…
-
Differential Discussions Guest Series: The Use of Chromogenic Factor X Assays for Monitoring Patients on Warfarin Therapy
Posted: April 11, 2025
David L. McGlasson, MS, MLS(ASCP) A recent episode of “Differential Discussions” digs into the utility of the chromogenic factor X (CFX) assay for monitoring patients on oral anticoagulant therapy (OAT). Data from previous studies and a case study were discussed. A study was presented that compared International Normalized Ratio (INR) values with CFX results, to…
-
Through the Lens of CK18: Reflections on the AASLD ETC 2025: metALD and ALD
Posted: March 31, 2025
— Contributed by Olivia Stricker, PhD and Jessica Tuohy, PhD The 2025 AASLD Emerging Topics Conference in Las Vegas delivered an invigorating discussion on one of the most pressing challenges in hepatology today—metabolic dysfunction-associated alcohol-related liver disease (metALD) and the evolving landscape of ALD clinical trials. As research advances, our understanding of these diseases continues…
-
The (im)Balance of NETosis, Platelets, VWF, and ADAMTS13 During Immunothrombosis
Posted: December 10, 2024
-Contributed by Abi Kasberg, PhD Immunothrombosis defines the delicate intersection of innate immunity and coagulation. This complex bidirectional interaction between the immune system and clotting components activate each other, leading to abnormal clotting events when unbalanced. A central component to immunothrombosis is the NETosis response of activated neutrophils that result in the expulsion of neutrophil…
-
Type 2 Diabetes and MASH: Unraveling the Metabolic Crosstalk
Posted: December 10, 2024
-Contributed by Olivia Stricker, PhD and Abi Kasberg, PhD The relationship between metabolic disorders and liver disease is striking. Liver disease affects 75% of individuals with type 2 diabetes (T2D), making metabolic disorders the most common underlying cause of liver disease in the U.S (Gobejishvili et al. 2024). The liver diseases associated with T2D range…
-
Extended half-life (EHL) testing for FVIII and FIX therapies
Posted: November 13, 2024
David McGlasson The complexities of testing for hemophilia A and B are vast. This Clot Club post serves as an overview of what the laboratory must consider when testing for new EHL products. When comparing different methods used to determine FVIII and FIX activity, the testing laboratory should evaluate the calibrators used, individual kit…
-
Connect with DiaPharma – see where we’ll be!
Posted: September 12, 2024
It’s Not Just Support. It’s Solutions. VISIT DIAPHARMA AT THESE UPCOMING EVENTS! Connect with DiaPharma to discuss all the latest in hemostasis and liver disease. Interested in learning more about the cytokeratin 18 (CK18) biomarker assays, M30® Apoptosense and M65 ELISA®, for MASH, ALD/AH, DILI , or any of our other cutting edge products? Make…
-
Connect with DiaPharma – see where we’ll be!
Posted: September 11, 2024
It’s Not Just Support. It’s Solutions. VISIT DIAPHARMA AT THESE UPCOMING EVENTS! Connect with DiaPharma to discuss all the latest in hemostasis and liver disease. Interested in learning more about the Ceveron s100*, the FDA-cleared T-TAS 01, Technozym ADAMTS13 Activity ELISA for IVD use, M30® Apoptosense ELISA for liver damage, or any of our other…
Solutions for Detection of Apoptosis in Oncology Xenograft Models
At DiaPharma, we specialize in biomarker assays designed to advance oncology research. One of the hallmarks of cancer is the evasion of apoptosis by tumor cells—making the detection of cellular death, especially apoptosis, a critical readout in the evaluation of anti-cancer therapies.Xenograft models are widely used in oncology research to study cancer therapies in vivo. However, methods for evaluating the effect of potential drug candidates on tumor growth—such as volume measurements, imaging, or immunohistochemical staining—are often imprecise, expensive, technically demanding, or require sacrificing the xenograft host.
An alternative is the M30 Apoptosense® ELISA*
What is the M30 Apoptosense® ELISA?
This blood-based biomarker assay utilizes the M30® antibody which specifically detects a caspase-cleaved fragment of cytokeratin 18 (CK18), a cytoskeletal protein expressed in epithelial cells and cleaved by caspases early during apoptosis. The cleaved CK18 fragment (ccK18) is released into the bloodstream, and its concentration in serum or plasma measured with the M30 Apoptosense® ELISA correlates with the extent of epithelial cell apoptosis.
Why Choose the M30 Apoptosense® ELISA for Use with Your Xenograft Models?
The M30® antibody is highly specific for human ccK18 and does not cross-react with murine proteins, enabling precise detection of apoptosis of human tumor cells within xenograft models. Minimally invasive blood sampling allows for longitudinal assessment of treatment response. The assay provides sensitive, quantitative measurements to evaluate dose- and time-dependent effects of potential drug candidates. Incorporating the M30® biomarker offers a robust, translational tool to strengthen efficacy assessments—particularly valuable for bridging preclinical findings to clinical application. We would be happy to provide more detailed information tailored to your research. Please don’t hesitate to reach out to our Scientists or your local DiaPharma Territory Manager*For research use only in US and Canada. Not for use in diagnostic procedures.